---
title: "Cytosorbents Corporation (CTSO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CTSO.US.md"
symbol: "CTSO.US"
name: "Cytosorbents Corporation"
industry: "Health Care Equipment"
datetime: "2026-05-20T12:57:07.964Z"
locales:
  - [en](https://longbridge.com/en/quote/CTSO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CTSO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CTSO.US.md)
---

# Cytosorbents Corporation (CTSO.US)

## Company Overview

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.cytosorbents.com](https://www.cytosorbents.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.59)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 100 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5.29% |  |
| Net Profit YoY | 26.45% |  |
| P/B Ratio | 13.53 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 29675034.11 |  |
| Revenue | 37200000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -141.58% | E |
| Profit Margin | -31.85% | E |
| Gross Margin | 69.16% | A |
| Revenue YoY | 5.29% | C |
| Net Profit YoY | 26.45% | B |
| Total Assets YoY | -20.12% | E |
| Net Assets YoY | -84.91% | E |
| Cash Flow Margin | 85.02% | C |
| OCF YoY | 5.29% | C |
| Turnover | 0.81 | B |
| Gearing Ratio | 94.59% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Cytosorbents Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "5.29%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "26.45%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "13.53",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "29675034.11",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "37200000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-141.58%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-31.85%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "69.16%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "5.29%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "26.45%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-20.12%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-84.91%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "85.02%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "5.29%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.81",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "94.59%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.50 | 106/183 | - | - | - |
| PB | 13.53 | 131/183 | 5.56 | 4.89 | 4.44 |
| PS (TTM) | 0.80 | 22/183 | 1.69 | 1.34 | 1.09 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 33% |
| Hold | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.47 |
| Highest Target | 10.00 |
| Lowest Target | 0.75 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CTSO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CTSO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CTSO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CTSO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**